

L1

1 S US 20080161312/PN

L1 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Preparation of pyrrolo[2,3-b]pyrazines as kinase inhibitors for treatment

of neurodegenerative and proliferative disorders

ACCESSION NUMBER: 2004:117251 HCAPLUS Full-text

DOCUMENT NUMBER: 140:163892

TITLE: Preparation of pyrrolo[2,3-b]pyrazines as kinase

inhibitors for treatment of neurodegenerative

and

proliferative disorders

INVENTOR(S): Meijer, Laurent; Vierfond, Jean-Michel;

Mettey, Yvette

PATENT ASSIGNEE(S): Centre National De La Recherche Scientifique (Cnrs),

Fr.

SOURCE: Eur. Pat. Appl., 35 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1388541	A1	20040211	EP 2002-292019	
20020809				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CA 2495060	A1	20040226	CA 2003-2495060	
20030808				
WO 2004016614	A2	20040226	WO 2003-EP9515	
20030808				
WO 2004016614	A3	20040506		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,				
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,				
TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

AU 2003271566 A1 20040303 AU 2003-271566
 20030808
 EP 1527077 A2 20050504 EP 2003-753362

FILE 'REGISTRY' ENTERED AT 10:34:42 ON 22 SEP 2009
 L2 STRUCTURE UPLOADED

=>


Uploading C:\Program Files\STNEXP\Queries\10524044 search 9222009 1.str




L3 3 S L2 SSS SAM
 L4 66 S L2 SSS FULL

FILE 'HCAPLUS' ENTERED AT 10:35:46 ON 22 SEP 2009
 L5 29 S L4
 L6 5 S L5 AND (PY<2002 OR AY<2002 OR PRY<2002)

L6 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Synthesis of heterocyclic compounds employing microwave technology
 GI



I



II

AB The heterocycles I (X = N, CR4, Y and Z = CH, CHR3, W = N; X = CR4, Y and W = N, Z = CR3; Y = CR3, Z and W = N, X = N, CR4; Y = bond, W = N, Z = CR5, X = O, S, NR6; Y = bond, W = N, X = CR4, Z = O, S, NR7; Y = bond, W = O, X = CR4, Z = N, CR5; Y = bond, W = O, X = N, Z = CR5; R1 = aryl, heteroaryl which may be optionally substituted; R2 = H, acyl, cyano, halo, alkenyl, etc.; R3 = H, aryl cyano, halo, heteroaryl, etc.; R4 = H, halo, cyano, OH, nitro, etc.; R5 = cyano, H, amino, etc., R6 = H, cyano,, alkyl, cycloalkyl, CO2H, carbamoyl, etc.; R7 = H, alkyl) were prepared using microwave energy. Thus, a microwave tube was charged with 6-(4-trifluoromethylsulfonyloxyphenyl)-5H-pyrrolo[2,3-b]pyrazine, pyrrolidine and dioxane and DMF, and heated at 200° in an

microwave oven for 1 h to give 6-(4-pyrrolidinophenyl)-5H-pyrrolo[2,3-b]pyrazine (II).

ACCESSION NUMBER: 2003:5959 HCAPLUS Full-text
DOCUMENT NUMBER: 138:73275
TITLE: Synthesis of heterocyclic compounds employing microwave technology
INVENTOR(S): Majid, Tahir Nadeem; Deprets, Stephanie D.; Pedgrift, Brian L.
PATENT ASSIGNEE(S): Aventis Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2003000690	A1	20030103	WO 2002-US20206	
20020625 <--				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002310513	A1	20030108	AU 2002-310513	
20020625 <--				
PRIORITY APPLN. INFO.:			US 2001-300733P	P
20010625 <--				
			GB 2001-19307	A
20010808 <--				
			WO 2002-US20206	W
20020625				
OTHER SOURCE(S):	CASREACT 138:73275; MARPAT 138:73275			
IC ICM C07D471-04				
ICS C07D487-04; B01J019-12				
CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))				
Section cross-reference(s): 27				
IT 479552-38-0P 479552-40-4P 479554-13-7P 480423-10-7P				
480423-12-9P 480423-13-0P 480423-25-4P				
RL: IMF (Industrial manufacture); SPN (Synthetic preparation);				
PREP				
(Preparation)				

(synthesis of heterocyclic compds. employing microwave technol.)

IT 55052-24-9P 55052-28-3P 105956-24-9P 107718-01-4P 143122-18-3P

191411-51-5P 191411-55-9P 191411-66-2P 348637-52-5P
348639-62-0P 348639-50-9P 348639-51-0P 348639-70-3P
348640-05-1P 348640-06-2P 348640-07-3P 348640-26-6P
348640-27-7P

348640-60-8P 348640-71-1P 479551-45-6P
479551-48-9P 479552-39-1P 480423-16-3P 480423-17-4P
480423-18-5P 480423-19-6P 480423-20-9P 480423-21-0P
480423-22-1P

480423-23-2P 480423-24-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT
(Reactant or reagent)


(synthesis of heterocyclic compds. employing microwave technol.)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE
FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE

RE FORMAT

L6 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Preparation of azaindoles as protein kinase inhibitors
GI



AB The invention is directed to physiologically active azaindoles (shown as I; variables defined below; e.g. 6-(5-methoxy-1-methyl-1H-indol-3-yl)-5H-pyrrolo[2,3-b]pyrazine) and compounds containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs. Such compounds and compounds have valuable pharmaceutical properties, in particular the ability to inhibit kinases, especially Syk, FAK, KDR, Aurora2 and IGF1R (data given in general rather than for specific I). Although the methods of preparation are not claimed, >100 example preparations of intermediates and I are included. For I: R1 = aryl or heteroaryl each optionally substituted by ≥1 groups = alkylendioxy, alkenyl, alkenyloxy, alkynyl, aryl, cyano, halo, hydroxy, heteroaryl, heterocycloalkyl, nitro, R4, -C(O)R, -C(O)OR5, -C(O)NY1Y2, -NY1Y2, -N(R6)C(O)R7, -N(R6)C(O)NY3Y4, -N(R6)C(O)OR7, -N(R6)SO2R7, -N(R6)SO2NY3Y4, -SO2NY1Y2 and -Z2R. R2 = H, acyl, cyano, halo, lower alkenyl, -Z2R4, -SO2NY3Y4, -NY1Y2 or lower alkyl optionally substituted by aryl, cyano, heteroaryl, heterocycloalkyl, hydroxy, -Z2R4, -C(O)NY1Y2, -C(O)R, -CO2R8, -



NY3Y4, -N(R6)C(O)R, -N(R6)C(O)NY1Y2, -N(R6)C(O)OR7, -N(R6)SO2R7, -
 N(R6)SO2NY3Y4, -SO2NY1Y2 and ≥ 1 halogen atoms. R3 = H, aryl,
 cyano, halo, heteroaryl, lower alkyl, -Z2R4, -C(O)OR5 or -
 C(O)NY3Y4. R4 = alkyl, cycloalkyl, cycloalkylalkyl,
 heterocycloalkyl or heterocycloalkylalkyl each optionally
 substituted by aryl, cycloalkyl, cyano, halo, heteroaryl,
 heterocycloalkyl, -CHO (or a 5- 6- or 7-membered cyclic acetal
 derivative thereof), -C(O)NY1Y2, -C(O)OR5, -NY1Y2, -N(R6)C(O)R7, -
 N(R6)C(O)NY3Y4, -N(R6)SO2R7, -N(R6)SO2NY3Y4, -Z3R7 and ≥ 1 hydroxy,
 alkoxy and carboxy. R5 = H, alkyl, alkenyl, aryl, arylalkyl,
 heteroaryl or heteroarylalkyl. R6 = H or lower alkyl; R7 = alkyl,
 aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl,
 heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; R8 = H
 or lower alkyl. R = aryl or heteroaryl; alkenyl; or alkyl,
 cycloalkyl, cycloalkylalkyl, heterocycloalkyl or
 heterocycloalkylalkyl each optionally substituted by aryl,
 cycloalkyl, cyano, halo, heteroaryl, heterocycloalkyl, -CHO (or a
 5- 6- or 7-membered cyclic acetal derivative thereof), -C(O)NY1Y2,
 -C(O)OR5, -NY1Y2, -N(R6)C(O)R7, -N(R6)C(O)NY3Y4, -N(R6)SO2R7, -
 N(R6)SO2NY3Y4, -Z3R7 and ≥ 1 hydroxy, alkoxy and carboxy. X1 = N,
 CH, C-aryl, C-heteroaryl, C-heterocycloalkyl, C-
 heterocycloalkenyl, C-halo, C-CN, C-R4, CNY1Y2, COH, CZ2R, CC(O)R,
 CC(O)OR5, CC(O)NY1Y2, CN(R8)C(O)R, CN(R6)C(O)OR7, CN(R6)C(O)NY3Y4,
 CN(R6)SO2NY3Y4, CN(R6)SO2R, CSO2NY3Y4, C-NO2, or C-alkenyl or C-
 alkynyl optionally substituted by ≥ 1 aryl, cyano, halo, hydroxy,
 heteroaryl, heterocycloalkyl, nitro, -C(O)NY1Y2, -C(O)OR5, -
 NNY1Y2, -N(R6)C(O)R7, -N(R6)C(O)NY3Y4, -N(R6)C(O)OR7, -N(R6)SO2R7,
 -N(R6)SO2NY3Y4, -SO2NY1Y2 and -Z2R4. Y1 and Y2 = H, alkenyl,
 aryl, cycloalkyl, heteroaryl or alkyl optionally substituted by ≥ 1
 aryl, halo, heteroaryl, heterocycloalkyl, hydroxy, -C(O)NY3Y4, -
 C(O)OR5, NY3Y4, -N(R6)C(O)R7, -N(R6)C(O)NY3Y4, -N(R6)SO2R7, -
 N(R6)SO2NY3Y4 and -OR7, or the group -NY1Y2 may form a cyclic
 amine. Y3 and Y4 = H, alkenyl, alkyl, aryl, arylalkyl,
 cycloalkyl, heteroaryl or heteroarylalkyl; or the group -NY3Y4 may
 form a cyclic amine; Z1 = O or S; Z2 = O or S(O)n; Z3 = O, S(O)n,
 NR6; n = 0-2.

ACCESSION NUMBER:	2003:5957 HCAPLUS <u>Full-text</u>
DOCUMENT NUMBER:	138:55984
TITLE:	Preparation of azaindoles as protein kinase
inhibitors	
INVENTOR(S):	Cox, Paul Joseph; Majid, Tahir Nadeem; Lai,
Justine	
	Yeun Quai; Morley, Andrew; Amendola, Shelley;
Deprets,	
	Stephanie Daniele; Edlin, Chris; Gardner,
Charles J.;	
	Kominos, Dorothea; Pedgrift, Brian Leslie;
Halley,	
	Frank; Gillespy, Timothy Alan; Edwards,
Michael;	
	Clerc, Francois Frederic; Nemecek, Conception;
	Houille, Olivier; Damour, Dominique; Bouchard,
Herve;	
	Bezard, Daniel; Carrez, Chantal
PATENT ASSIGNEE(S):	Aventis Pharma Limited, UK
SOURCE:	PCT Int. Appl., 373 pp.

CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000688	A1	20030103	WO 2002-GB2799	
20020620 <--				
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2451678	A1	20030103	CA 2002-2451678	
20020620 <--				
AU 2002302849	A1	20030108	AU 2002-302849	
20020620 <--				
EP 1397360	A1	20040317	EP 2002-730531	
20020620 <--				

L6 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Preparation of 6,5-fused bicyclic heterocycles as 15-lipoxygenase inhibitors
 GI




AB The title compds. [I; Q1-Q4 = CX, N; one or two of Q1-Q4 = N; or each of Q1-Q4 = CH2 and there is a C=C bond between the carbon atoms bearing Q1 and Y1, and Q4 and Z, resp.; X = H, halo, OH, etc.; one of Y1 and Y2 = CH, N, NH, S, O; and the other one of Y1 and Y2 = CWA_r (wherein W = a bond, O, S, etc.; Ar = Ph substituted at the 3- and 4-positions relative to W); Z = NR₅, S, O, C, CH (R₅ = H, alkyloxycarbonyl, aryloxycarbonyl, etc.)], useful for the

treatment of diseases responsive to the inhibition of the enzyme 15-lipoxygenase such as diseases with an inflammatory component, including atherosclerosis, diseases involving chemotaxis of monocytes, inflammation, stroke, coronary artery disease, asthma, arthritis, colorectal cancer, and psoriasis, were prepared and formulated. Thus, reacting 2,3-diaminopyridine with 4-methoxy-3-nitrobenzoic acid in the presence of POCl₃ followed by reduction of the resulting 5-(3H-imidazo[4,5-b]pyridin-2-yl)-2-methoxynitrobenzene with Zn/AcOH afforded II which showed 39% inhibition of 15-LO at 10μM in human lysate 15-LO assay.

ACCESSION NUMBER: 2001:923797 HCAPLUS Full-text
DOCUMENT NUMBER: 136:53746
TITLE: Preparation of 6,5-fused bicyclic heterocycles as 15-lipoxygenase inhibitors
INVENTOR(S): Picard, Joseph Armand; Roark, William Howard; Sliskovic, Drago Robert
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001096336	A2	20011220	WO 2001-US15112	
20010509 <--				
WO 2001096336	A3	20020328		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2412462	A1	20011220	CA 2001-2412462	
20010509 <--				
EP 1294718	A2	20030326	EP 2001-933269	
20010509 <--				



AB The invention is directed to compns. containing physiolo. active compds. of general formula [I; wherein R1 is (un)substituted aryl or heteroaryl; R2 represents hydrogen, acyl, cyano, halo, lower alkenyl or lower alkyl optionally substituted by a substituent selected from cyano, heteroaryl, heterocycloalkyl, -Z1R8, -CONY3Y4, -CO2R8, -NY3Y4, -N(R6)COR7, -N(R6)CONY3Y4, -N(R6)CO2R7, -N(R6)SO2R7, -N(R6)SO2NY3Y4 and one or more halogen atoms; R3 represents hydrogen, aryl, cyano, halo, heteroaryl, lower alkyl, -CO2R5 or -CONY3Y4; and X1 represents N, CH, C-halo, C-CN, C-R7, C-NY3Y4, C-OH, C-Z2R7, C-CO2R5, C-CONY3Y4, C-N(R8)COR7, C-SO2NY3Y4, C-N(R8)SO2R7, C-alkenyl, C-alkynyl or C-NO2; wherein R5 represents hydrogen, alkyl, alkenyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl; R6 represents hydrogen or lower alkyl; R7 represents alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; R8 represents hydrogen or lower alkyl; represents; Y3 and Y4 are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl; or the group -NY3Y4 may form a cyclic amine; Z1 represents O or S; Z2 represents O or S(O)n; n is zero or an integer 1 or 2] and their prodrugs, and pharmaceutically acceptable salts and solvates of such compds. and their prodrugs. These compds. have valuable pharmaceutical properties, in particular the ability to inhibit protein kinases, especially Syk kinase, and are useful for the treatment of asthma, psoriasis, joint inflammation, and inflammatory bowel disease. Thus, a stirred solution of diisopropylamine (59.9 mL) in THF (1,400 mL), at -15 °C and under nitrogen, was treated with a solution of n-butyllithium in hexanes (131 mL, 1.6 M) over 25 min at <-10°. After stirring for 30 min the mixture was treated with methylpyrazine (26.8 g) over 15 min, then stirred for 1 h and then treated with a solution of 5-methoxy-1-methyl-1H-indole-3-carbonitrile (53 g) in THF (600 mL) over 1 h at <-10°, and the reaction mixture was allowed to warm to room temperature over 2 h and then stood overnight to give, after workup and flash chromatog., 6-(5-Methoxy-1-methyl-1H-indol-3-yl)-5H-pyrrolo[2,3-b]pyrazine (19.4 g) as a gray solid. I showed IC50 of 10-100 nM against Syk kinase.

ACCESSION NUMBER:	2001:489395 HCAPLUS <u>Full-text</u>
DOCUMENT NUMBER:	135:92651
TITLE:	Preparation of azaindoles as protein kinase inhibitors
INVENTOR(S):	Cox, Paul Joseph; Majid, Tahir Nadeem; Lai, Justine
	Yeun Quai; Morley, Andrew David; Amendola, Shelley;
	Deprets, Stephanie; Edlin, Chris
PATENT ASSIGNEE(S):	Aventis Pharma Ltd., UK
SOURCE:	PCT Int. Appl., 270 pp.


DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

CODEN: PIXXD2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001047922	A2	20010705	WO 2000-GB4993	
20001227 <--				
WO 2001047922	A3	20020117		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2395593	A1	20010705	CA 2000-2395593	
20001227 <--				
EP 1263759	A2	20021211	EP 2000-985695	
20001227				

L6 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Reactions of β -(lithiomethyl)azines with nitriles as a route to pyrrolopyridines, -quinolines, -pyrazines, -quinoxalines and -pyrimidines
 GI



AB Deprotonation of 3-methylpyridine, followed by reaction with benzonitrile, gives an intermediate which, on treatment with addnl. strong base, cyclizes to give 2-phenyl[1H]-pyrrolo[2,3-b]pyridine (I). The application of this type of reaction to a variety of nitriles and β -methylazines (pyridines, quinolines, pyridines, quinoxalines and pyrimidines) is described.

ACCESSION NUMBER: 1992:174021 HCAPLUS Full-text
 DOCUMENT NUMBER: 116:174021

ORIGINAL REFERENCE NO.: 116:29451a,29454a
 TITLE: Reactions of β -(lithiomethyl)azines with nitriles
 as a route to pyrrolopyridines, -quinolines, -pyrazines, -quinoxalines and -pyrimidines
 AUTHOR(S): Davis, Michael L.; Wakefield, Basil J.; Wardell, Jacklyn A.
 CORPORATE SOURCE: Dep. Chem. Appl. Chem., Univ. Salford, Salford, M5 4WT, UK
 SOURCE: Tetrahedron (1992), 48(5), 939-52
 CODEN: TETRAB; ISSN: 0040-4020
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 116:174021
 CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))
 IT 10586-52-4P 27257-18-7P 53872-97-2P 53873-01-1P 64802-09-1P
 78605-08-0P 78605-10-4P 86847-74-7P 139962-68-8P 139962-69-9P
 139962-70-2P 139962-71-3P 139962-72-4P 139962-73-5P
 139962-74-6P
 139962-75-7P 139962-76-8P 139962-77-9P 139962-78-0P
 139962-79-1P 139962-80-4P 139962-81-5P 139962-82-6P
 139962-83-7P
 139962-84-8P 139962-85-9P 139962-86-0P 139962-87-1P
 139962-88-2P
 139962-89-3P 139962-90-6P

L7 6 S L5 AND (PY<2003 OR AY<2003 OR PRY<2003)
 L8 1 S L7 NOT L6

L8 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Preparation of pyrrolo[2,3-b]pyrazines as kinase inhibitors for treatment of neurodegenerative and proliferative disorders
 ACCESSION NUMBER: 2004:117251 HCAPLUS Full-text
 DOCUMENT NUMBER: 140:163892
 TITLE: Preparation of pyrrolo[2,3-b]pyrazines as kinase inhibitors for treatment of neurodegenerative and proliferative disorders
 INVENTOR(S): Meijer, Laurent; Vierfond, Jean-Michel; Mettey, Yvette
 PATENT ASSIGNEE(S): Centre National De La Recherche Scientifique (Cnrs), Fr.
 SOURCE: Eur. Pat. Appl., 35 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

```

-----
EP 1388541      A1      20040211      EP 2002-292019
20020809 <--
R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
MC, PT,
      IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
CA 2495060      A1      20040226      CA 2003-2495060
20030808 <--
WO 2004016614   A2      20040226      WO 2003-EP9515
20030808 <--
WO 2004016614   A3      20040506
W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN,
      CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,
GE, GH,
      GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR,
      LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
NZ, OM,
      PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN,
      TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY,
      KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES,
      FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI,
SK, TR,
      BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG
AU 2003271566   A1      20040303      AU 2003-271566
20030808 <--
EP 1527077      A2      20050504      EP 2003-753362
20030808 <--
R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
MC, PT,
      IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2006502137   T      20060119      JP 2004-528508
20030808 <--
US 20080161312   A1      20080703      US 2005-524044
20051212 <--
PRIORITY APPLN. INFO.:
20020809 <--
EP 2002-292019      A
WO 2003-EP9515      W
20030808

```

```

L9          7 S L5 AND (PY<2004 OR AY<2004 OR PRY<2004)
L10         1 S L9 NOT (L6 OR L7)

```

```

FILE 'REGISTRY' ENTERED AT 10:40:34 ON 22 SEP 2009
E 139962-77-9/RN
SET EXPAND CONTINUOUS
L11         1 S E3
E 348637-52-5/RN
L12         1 S E15
E 348637-50-3/RN

```

L13	1 S E27 E 348638-57-3/RN
L14	1 S E3
L15	1 S E39 E 348638-59-5/RN
L16	1 S E51 E 348638-62-0/RN
L17	1 S E63 E 348638-80-2/RN
L18	1 S E75 E 348638-61-9/RN
L19	1 S E87 E 348638-63-1/RN
L20	1 S E99 E 348638-58-4/RN
L21	1 S E111 E 348638-60-8/RN
L22	1 S E123 E 348638-61-9/RN
L23	1 S E135 E 348638-98-2/RN
L24	1 S E147 E 348638-94-8/RN
L25	1 S E159 E 381249-99-6/RN
L26	1 S E171 E 381250-00-6/RN
L27	1 S E183 E 381250-01-7/RN
L28	1 S E195 E 381250-02-8/RN
L29	1 S E207 E 381250-03-9/RN
L30	1 S E219 E 348640-77-7/RN
L31	1 S E231 E 348640-71-1/RN
L32	1 S E243 E 348640-64-2/RN
L33	1 S E255 E 348640-60-8/RN
L34	1 S E267 E 348639-72-5/RN
L35	1 S E279 E 348639-75-8/RN
L36	1 S E291 E 348639-70-3/RN
L37	1 S E303 E 479551-49-0/RN
L38	1 S E315 E 479551-45-6/RN
L39	1 S E327 E 479551-48-9/RN
L40	1 S E339 E 479552-24-4/RN
L41	1 S E351

FILE 'REGISTRY' ENTERED AT 10:57:48 ON 22 SEP 2009

L42 STRUCTURE UPLOADED

L43 0 S L42 SSS SAM

L44 0 S L42 SSS FULL


L45 STRUCTURE UPLOADED

L45 STRUCTURE UPLOADED

=> d 145

L45 HAS NO ANSWERS

L45 STR



G1 Ak,Me,CH₂,CH,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu

G2 X,Ak,OH,MeO,EtO,n-PrO,i-PrO,n-BuO,i-BuO,s-BuO,t-BuO,C,H,O,Cl,Br,F,I

L46 0 S L45 SSS SAM

L47 0 S L45 SSS FULL

L48 STRUCTURE UPLOADED

L49 0 S L48 SSS SAM

L50 0 S L48 SSS FULL


L51 STRUCTURE UPLOADED

L51 STRUCTURE UPLOADED

=> d 151

L51 HAS NO ANSWERS

L51 STR



G1

G2 X,Ak,OH,MeO,EtO,n-PrO,i-PrO,n-BuO,i-BuO,s-BuO,t-BuO,C,H,O,Cl,Br,F,I

G3 Me,Et,n-Pr,i-Pr,n-Bu,i-Bu

L52 0 S L51 SSS SAM

L53 0 S L51 SSS FULL

L54 STRUCTURE UPLOADED

L55 0 S L54 SSS SAM

L56 0 S L54 SSS FULL
 L57 STRUCTURE UPLOADED
 L58 0 S L57 SSS SAM
 L59 0 S L57 SSS FULL
 L60 STRUCTURE UPLOADED
 L61 0 S L60 SSS SAM
 L62 22 S L60 SSS FULL
 L63 0 S SSS SAM L62 SUB=L4
 L64 0 S SSS FULL L62 SUB=L4


FILE 'HCAPLUS' ENTERED AT 11:13:48 ON 22 SEP 2009

L65 5 S L62
 L66 3 S L65 AND (PY<2002 OR AY<2002 OR PRY<2002)
 L67 3 S L65 AND (PY<2003 OR AY<2003 OR PRY<2003)
 L68 0 S L67 NOT L66
 L69 5 S L65 AND (PY<2004 OR AY<2004 OR PRY<2004)
 L70 2 S L69 NOT L67

FILE 'REGISTRY' ENTERED AT 11:17:40 ON 22 SEP 2009

E 28885-12-3/RN
 L71 1 S E363
 E 28885-13-4/RN
 L72 1 S E375
 E 28885-14-5/RN
 L73 1 S E387
 E 29025-75-0/RN
 L74 1 S E399
 E 75163-79-0/RN
 L75 1 S E411
 E 75163-80-3/RN
 L76 1 S E423
 E 75174-60-6/RN
 L77 1 S E435
 E 521983-49-3/RN
 L78 1 S E 447
 E 521983-90-4/RN
 L79 1 S E459
 E 521984-67-8/RN
 L80 1 S E471
 E 521985-07-9/RN
 L81 1 S E483
 E 521985-08-0/RN
 L82 1 S E495
 E 521985-06-8/RN
 L83 1 S E507
 E 496864-25-6/RN
 L84 1 S E519

L84 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 496864-25-6 REGISTRY
 ED Entered STN: 04 Mar 2003
 CN 5H-Pyrrolo[2,3-b]pyrazine, 5-methyl-6-phenyl- (CA INDEX NAME)
 MF C13 H11 N3
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



FILE 'HCAPLUS' ENTERED AT 11:22:38 ON 22 SEP 2009
L85 2 S L84

L85 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Preparation of indole- and pyrrolo[2,3-b]pyridine-containing amide
derivatives as antagonists of transforming growth factor- β
(TGF- β)

ACCESSION NUMBER: 2003:356416 HCAPLUS Full-text

DOCUMENT NUMBER: 138:368914

TITLE: Preparation of indole- and
pyrrolo[2,3-b]pyridine-containing amide

derivatives as

antagonists of transforming growth factor- β
(TGF- β)

INVENTOR(S): Maruyama, Yasufumi; Hirabayashi, Kazuko; Hori,
Katsutoshi

PATENT ASSIGNEE(S): Nippon Shinyaku Co., Ltd., Japan

SOURCE: PCT Int. Appl., 123 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003037862	A1	20030508	WO 2002-JP11232	
20021029				
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002344424	A1	20030512	AU 2002-344424	
20021029				

EP 1452525 A1 20040901 EP 2002-779936
 20021029
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
 MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 US 20050014942 A1 20050120 US 2004-494622
 20040430
 PRIORITY APPLN. INFO.: JP 2001-332942 A
 20011030 JP 2002-127771 A
 20020430 WO 2002-JP11232 W
 20021029
 OTHER SOURCE(S): MARPAT 138:368914
 IC ICM C07D209-18
 ICS C07D209-42; C07D401-04; C07D401-06; C07D401-12; C07D401-14;
 C07D403-12; C07D403-14; C07D405-04; C07D405-12; C07D405-14;
 C07D409-14; C07D413-14; C07D417-14; C07D471-04; A61K031-404;
 A61K031-437; A61K031-454; A61K031-4725; A61K031-496
 CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 63
 IT 401-25-2P, N-(4-Fluoro-2-methylphenyl)benzamide 452-71-1P,
 4-Fluoro-2-methylaniline 2739-04-0P, N-Methyl-4-
 methylformanilide
 2922-07-8P 10586-52-4P, 2-Phenyl-1H-pyrrolo[2,3-b]pyridine
 13924-95-3P
 24006-21-1P, 1-Methyl-1-(4-methylphenyl)hydrazine 25797-03-9P
 27257-15-4P, 1-Methyl-1H-pyrrolo[2,3-b]pyridine 33332-25-1P
 56700-70-0P, 3-(tert-Butoxycarbonylamino)pyridine 59541-83-2P
 73781-91-6P, 6-Chloronicotinic acid methyl ester 78605-10-4P
 83515-06-4P 84875-83-2P, N-Methyltoluidine 112671-47-3P
 132144-03-7P
 180253-66-1P 221353-39-5P 263570-28-1P 287114-19-6P
 287114-20-9P
 288254-70-6P 288254-71-7P 288254-79-5P 496864-25-6P
 521984-94-1P 521984-95-2P 521984-96-3P 521984-97-4P
 521984-98-5P
 521984-99-6P 521985-00-2P 521985-01-3P 521985-02-4P
 521985-03-5P
 521985-04-6P 521985-05-7P 521985-06-8P 521985-07-9P
 521985-08-0P
 521985-09-1P 521985-10-4P 521985-11-5P 521985-12-6P
 521985-13-7P
 521985-14-8P 521985-15-9P 521985-16-0P 521985-18-2P
 521985-19-3P
 521985-20-6P 521985-21-7P 521985-22-8P 521985-23-9P
 521985-24-0P
 521985-25-1P 521985-26-2P 521985-27-3P 521985-28-4P
 521985-29-5P
 521985-30-8P 521985-31-9P 521985-32-0P 521985-35-3P
 521985-50-2P
 521985-51-3P 522600-69-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP
 (Preparation); RACT
 (Reactant or reagent)
 (preparation of indole- and pyrrolo[2,3-b]pyridine-containing
 amide derivs. as

antagonists of transforming growth factor- β for treatment of
pulmonary fibrosis, scleroderma, systemic scleroderma, and
nephritis)

OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE
THIS RECORD

(7 CITINGS)

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE
FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT

L85 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study,
Crystal

Structure in Complex with CDK2, Enzyme Selectivity, and Cellular
Effects

ACCESSION NUMBER: 2002:954429 HCAPLUS Full-text

DOCUMENT NUMBER: 138:147177

TITLE: Aloisines, a New Family of CDK/GSK-3
Inhibitors. SAR

Study, Crystal Structure in Complex with CDK2,
Enzyme

Selectivity, and Cellular Effects

AUTHOR(S): Mettey, Yvette; Gompel, Marie; Thomas,
Virginie;

Garnier, Matthieu; Leost, Maryse; Ceballos-
Picot,

Irene; Noble, Martin; Endicott, Jane;
Vierfond,

Jean-Michel; Meijer, Laurent

CORPORATE SOURCE: Faculte de Medecine et de Pharmacie, Poitiers,
86005,

Fr.
SOURCE: Journal of Medicinal Chemistry (2003), 46(2),
222-236

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:147177

CC 1-3 (Pharmacology)

Section cross-reference(s): 7, 28

IT 64802-09-1P 78605-10-4P 78605-13-7P 139962-68-8P 139962-
77-9P

139962-78-0P 348637-26-3P 348637-46-7P 348637-50-3P

348637-66-1P

348637-69-4P 348637-75-2P 479551-48-9P 496863-90-2P

496863-91-3P

496863-92-4P 496863-93-5P 496863-94-6P 496863-95-7P

496863-96-8P

496863-97-9P 496863-98-0P 496863-99-1P 496864-00-7P

496864-01-8P

496864-02-9P 496864-03-0P 496864-04-1P 496864-05-2P

496864-06-3P

496864-07-4P 496864-08-5P 496864-09-6P 496864-10-9P

496864-11-0P

496864-12-1P 496864-13-2P 496864-15-4P 496864-16-5P

496864-17-6P
 496864-18-7P 496864-19-8P 496864-20-1P 496864-21-2P
 496864-22-3P
 496864-23-4P 496864-24-5P 496864-25-6P 496864-26-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
 THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation);
 USES
 (Uses)
 (preparation and structure activity relationships of aloisines
 as CDK/GSK-3
 inhibitors.)

E MEIJER LAURENT?/AU
 L86 236 S E530
 L87 4 S L86 AND L5
 L88 1 S L87 AND (PY<2003 OR AY<2003 OR PRY<2003)

L88 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Preparation of pyrrolo[2,3-b]pyrazines as kinase inhibitors for
 treatment
 of neurodegenerative and proliferative disorders
 ACCESSION NUMBER: 2004:117251 HCAPLUS Full-text
 DOCUMENT NUMBER: 140:163892
 TITLE: Preparation of pyrrolo[2,3-b]pyrazines as
 kinase
 inhibitors for treatment of neurodegenerative
 and
 proliferative disorders
 INVENTOR(S): Meijer, Laurent; Vierfond, Jean-Michel;
 Mettey, Yvette
 PATENT ASSIGNEE(S): Centre National De La Recherche Scientifique
 (Cnrs),
 Fr.
 SOURCE: Eur. Pat. Appl., 35 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1388541	A1	20040211	EP 2002-292019	
20020809 <--				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CA 2495060	A1	20040226	CA 2003-2495060	
20030808 <--				
WO 2004016614	A2	20040226	WO 2003-EP9515	
20030808 <--				
WO 2004016614	A3	20040506		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,				


GE, GH,
 LK, LR,
 NZ, OM,
 TM, TN,
 RW: TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 AZ, BY, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 EE, ES, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 SK, TR, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI,

E VIERFOND JEAN?/AU
 L89 41 S E542
 L90 3 S L89 AND L5
 L91 1 S L90 AND (PY<2003 OR AY<2003 OR PRY<2003)
 L92 0 S L91 NOT L88
 E METTEY YVETTE?/AU
 L93 43 S E553-E554
 L94 3 S L93 AND L5
 L95 1 S L94 AND (PY<2003 OR AY<2003 OR PRY<2003)
 L96 0 S L95 NOT L88

L1 STRUCTURE UPLOADED
 L2 0 S L1 SSS SAM
 L3 0 S L1 SSS FULL
 L4 STRUCTURE UPLOADED

L4 STRUCTURE UPLOADED

=> d 14
 L4 HAS NO ANSWERS
 L4 STR



L5 1 S L4 SSS SAM
 L6 13 S L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 10:11:41 ON 24 SEP 2009
 L7 14 S L6
 L8 7 S L7 AND (PY<2002 OR AY<2002 OR PRY<2002)

L8 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
 TI Preparation of azaindoles as protein kinase inhibitors
 ACCESSION NUMBER: 2003:5957 CAPLUS Full-text

DOCUMENT NUMBER: 138:55984
 TITLE: Preparation of azaindoles as protein kinase inhibitors
 INVENTOR(S): Cox, Paul Joseph; Majid, Tahir Nadeem; Lai, Justine
 Deprets,
 Charles J.;
 Halley,
 Michael;
 Clerc, Francois Frederic; Nemecek, Conception; Houille, Olivier; Damour, Dominique; Bouchard, Herve;
 Bezard, Daniel; Carrez, Chantal
 PATENT ASSIGNEE(S): Aventis Pharma Limited, UK
 SOURCE: PCT Int. Appl., 373 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000688	A1	20030103	WO 2002-GB2799	
20020620 <--				
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

L8 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
 TI Preparation of azaindoles as protein kinase inhibitors
 ACCESSION NUMBER: 2001:489395 CAPLUS Full-text
 DOCUMENT NUMBER: 135:92651
 TITLE: Preparation of azaindoles as protein kinase inhibitors
 INVENTOR(S): Cox, Paul Joseph; Majid, Tahir Nadeem; Lai, Justine

Shelley;
 Yeun Quai; Morley, Andrew David; Amendola,
 Deprets, Stephanie; Edlin, Chris
 PATENT ASSIGNEE(S): Aventis Pharma Ltd., UK
 SOURCE: PCT Int. Appl., 270 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001047922	A2	20010705	WO 2000-GB4993	
20001227 <--				
WO 2001047922	A3	20020117		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2395593	A1	20010705	CA 2000-2395593	
20001227 <--				
EP 1263759	A2	20021211	EP 2000-985695	
20001227 <--				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

L8 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
 TI 2-Aryl-3-alkylpyrrolo[2,3-b]quinoxalines
 ACCESSION NUMBER: 1983:405647 CAPLUS Full-text
 DOCUMENT NUMBER: 99:5647
 ORIGINAL REFERENCE NO.: 99:1033a,1036a
 TITLE: 2-Aryl-3-alkylpyrrolo[2,3-b]quinoxalines
 INVENTOR(S): Andreichikov, Yu. S.; Pitirimova, S. G.; Tokmakova, T.
 N.; Nalimova, Yu. A.
 PATENT ASSIGNEE(S): Perm Pharmaceutical Institute, USSR
 SOURCE: U.S.S.R. From: Otkrytiya, Izobret., Prom. Obraztsy,
 Tovarnye Znaki 1982, (45), 101.
 CODEN: URXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Russian

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

SU 979350	A1	19821207	SU 1981-3241244	
19810129 <--				
PRIORITY APPLN. INFO.:			SU 1981-3241244	
19810129 <--				
IC C07D487-04				
CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))				
IT 85677-58-3P 85677-59-4P 85677-60-7P 85677-61-8P				
RL: SPN (Synthetic preparation); PREP (Preparation)				
(preparation of)				

L8 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
TI Ring opening or rearrangement versus N-oxidation in the action of peracids
upon pyrrolo[2,3-b]pyridines, pyrrolo[2,3-b]pyrazines, and triazolo[1,5-a]- and triazolo[4,3-a]pyrazine. Some chemical and spectroscopic properties of the triazolopyrazines and their N-oxides
ACCESSION NUMBER: 1980:532395 CAPLUS Full-text
DOCUMENT NUMBER: 93:132395
ORIGINAL REFERENCE NO.: 93:21109a,21112a
TITLE: Ring opening or rearrangement versus N-oxidation in
the action of peracids upon pyrrolo[2,3-b]pyridines,
pyrrolo[2,3-b]pyrazines, and triazolo[1,5-a]- and triazolo[4,3-a]pyrazine. Some chemical and spectroscopic properties of the triazolopyrazines and their N-oxides
AUTHOR(S): Hardy, Christopher R.; Parrick, John
CORPORATE SOURCE: Sch. Chem., Brunel Univ., Uxbridge, UB3 3PH, UK
SOURCE: Journal of the Chemical Society, Perkin Transactions
1: Organic and Bio-Organic Chemistry (1972-1999) (1980), (2), 506-11
CODEN: JCPRB4; ISSN: 0300-922X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 93:132395
CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))
IT 56015-26-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidative ring cleavage of)
OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

TI Mass spectrometry of pyrrolo[2,3-b]pyrazines and pyrazino[2,3-b]indole

ACCESSION NUMBER: 1978:88627 CAPLUS Full-text

DOCUMENT NUMBER: 88:88627

ORIGINAL REFERENCE NO.: 88:13887a,13890a

TITLE: Mass spectrometry of pyrrolo[2,3-b]pyrazines and

pyrazino[2,3-b]indole

AUTHOR(S): Clark, B. A. J.; Parrick, J.

CORPORATE SOURCE: Sch. Chem., Brunel Univ., Uxbridge, UK

SOURCE: Organic Mass Spectrometry (1977), 12(7), 421-3

CODEN: ORMSBG; ISSN: 0030-493X

DOCUMENT TYPE: Journal

LANGUAGE: English

CC 22-2 (Physical Organic Chemistry)

IT 245-10-3 4745-93-1 20321-99-7 56015-24-8 56015-26-0

56015-27-1 56015-28-2 56015-29-3 65623-46-3

RL: PRP (Properties)

(mass spectrum of)

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD

(1 CITINGS)

L8 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

TI Formation of certain substituted 5H-pyrrolo[2,3-b]pyrazines by thermal

cyclization of pyrazinylhydrazones and a route to

5H-pyrazino[2,3-b]indole; a synthesis of 5H-pyrrolo[2,3-b]pyrazine and

some of its properties

ACCESSION NUMBER: 1976:592666 CAPLUS Full-text

DOCUMENT NUMBER: 85:192666

ORIGINAL REFERENCE NO.: 85:30815a,30818a

TITLE: Formation of certain substituted 5H-pyrrolo[2,3-b]pyrazines by thermal

cyclization of

pyrazinylhydrazones and a route to

5H-pyrazino[2,3-b]indole; a synthesis of

5H-pyrrolo[2,3-b]pyrazine and some of its

properties

AUTHOR(S): Clark, Bernard A. J.; Parrick, John; Dorgan, Roderick

J. J.

CORPORATE SOURCE: Sch. Chem., Brunel Univ., Uxbridge, UK

SOURCE: Journal of the Chemical Society, Perkin

Transactions

1: Organic and Bio-Organic Chemistry (1972-

1999) (

1976), (13), 1361-3

CODEN: JCPRB4; ISSN: 0300-922X

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 85:192666

CC 28-18 (Heterocyclic Compounds (More Than One Hetero Atom))

IT 245-10-3P 4121-22-6P 4745-93-1P 20321-99-7P 56015-24-8P

56015-25-9P 56015-26-0P 56015-27-1P 56015-28-2P

56015-29-3P 56015-30-6P 56015-31-7P 60914-75-2P 60914-76-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE
THIS RECORD

(7 CITINGS)

L8 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

TI Pyrrolo[2,3-b]pyrazines and pyrazino[2,3-b]indole

ACCESSION NUMBER: 1975:409991 CAPLUS Full-text

DOCUMENT NUMBER: 83:9991

ORIGINAL REFERENCE NO.: 83:1669a,1672a

TITLE: Pyrrolo[2,3-b]pyrazines and pyrazino[2,3-b]indole

AUTHOR(S): Clark, Bernard A. J.; Dorgan, Roderick J.;
Parrick,

John

CORPORATE SOURCE: Sch. Chem., Brunel Univ., Uxbridge, UK

SOURCE: Chemistry & Industry (London, United Kingdom)

(

1975), (5), 215-16

CODEN: CHINAG; ISSN: 0009-3068

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 83:9991

CC 28-18 (Heterocyclic Compounds (More Than One Hetero Atom))

IT 245-10-3P 4121-22-6P 4745-93-1P 20321-99-7P 56015-24-8P

56015-25-9P 56015-26-0P 56015-27-1P 56015-28-2P

56015-30-6P 56015-31-7P 56111-34-3P 56174-46-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

FILE 'REGISTRY' ENTERED AT 10:13:34 ON 24 SEP 2009

E 348637-51-4/RN

SET EXPAND CONTINUOUS

L9 1 S E3

E 348637-49-0/RN

L10 1 S E15